ClinicalTrials.gg

Small Cell Lung Carcinoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,302 studies for Small Cell Lung Carcinoma across more than 10 countries. 365 are recruiting or about to start. 879 of them are mainly about Small Cell Lung Carcinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 9,787 studies for Small Cell Lung Carcinoma. How that becomes 1,302 here

This page counts the studies the registry files under Small Cell Lung Carcinoma, and those it files under no condition that list Small Cell Lung Carcinomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 9,787Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −31List Small Cell Lung Carcinoma as a condition, but the registry did not file them under itMost often written as “Small Cell Lung Cancer Extensive Stage” (6), “Extensive Stage Small Cell Lung Carcinoma” (3), and “Extensive Disease Small Cell Lung Cancer” (3). The registry filed 1 of them under no condition at all, and the others under other conditions only, most often Neoplasms (6) and Carcinoma, Non-Small-Cell Lung (6).
  3. −8,454Match it another way200 name it in the title, 26 in a keyword, and 8,228 by a synonym or other text the search reads.
  4. 1,302The count on this page94 of them list Small Cell Lung Carcinoma in their own words; the registry filed them under no condition.

Status

Completed
479
Recruiting
265
Terminated
155
Status unknown
147
Active, not recruiting
105
Not yet recruiting
90

Phase

Phase 2
640
Phase 1
421
Phase 3
140
Phase 4
12
Early Phase 1
10

Where

United States
630
China
365
Spain
141
France
120
Korea, Republic of
107
Canada
96

Who develops what

Add Small Cell Lung Carcinoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 100 programs from 67 companies, 75 with this as their studies’ main aim; 29 with a live phase 3 study; 19 primary completions in the next 12 months. Compare Novartis, Amgen and Boehringer Ingelheim here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07843940 · Boehringer Ingelheim · Phase 2 · live · background · “Carboplatin” · registered Sep 2026
  • NCT07802821 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Carboplatin” · registered Aug 2026
  • NCT07796100 · Zai Lab Limited · Phase 3 · live · background · “Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin” · registered Aug 2026
  • NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Carboplatin” · registered Jul 2026
  • NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
Eli Lilly and Company16% of its industry studies2124 studies
EtoposideRecent, repeated
Evidence
  • NCT07881705 · Simcere Pharmaceutical Group Limited · Phase 3 · live · background · “Etoposide Injection” · registered Oct 2026
  • NCT07843940 · Boehringer Ingelheim · Phase 2 · live · background · “Etoposide” · registered Sep 2026
  • NCT07802821 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Etoposide” · registered Aug 2026
  • NCT07796100 · Zai Lab Limited · Phase 3 · live · background · “Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin” · registered Aug 2026
  • NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
Hoffmann-La Roche14% of its industry studiesUS: off-patent, 5 generics marketed1720 studies
TopotecanRecent, repeated
Evidence
  • NCT07365241 · AbbVie · Phase 3 · live · comparator · “Topotecan” · registered Jan 2026
  • NCT07189455 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · comparator · “Topotecan” · registered Sep 2025
  • NCT07076095 · SUNHO(China)BioPharmaceutical CO., Ltd. · Phase 2 · live · background · “topotecan hydrochloride for injection” · registered Jul 2025
  • NCT06954246 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Topotecan” · registered Apr 2025
  • NCT06612151 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “topotecan hydrochloride for injection” · registered Sep 2024
GlaxoSmithKline55% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 1 generic authorized1314 studies
atezolizumabRecent, repeated
Evidence
  • NCT07796100 · Zai Lab Limited · Phase 3 · live · background · “Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin” · registered Aug 2026
  • NCT07707895 · Boehringer Ingelheim · Phase 2 · live · background · “Atezolizumab” · registered Jul 2026
  • NCT07654400 · Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 2 · live · background · “Atezolizumab” · registered Jun 2026
  • NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
  • NCT07472517 · Boehringer Ingelheim · Phase 3 · live · background · “atezolizumab” · registered Mar 2026
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)1214 studies
lurbinectedinRecent, repeated
Evidence
  • NCT07796100 · Zai Lab Limited · Phase 3 · live · background · “Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin” · registered Aug 2026
  • NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
  • NCT07365241 · AbbVie · Phase 3 · live · comparator · “Lurbinectedin” · registered Jan 2026
  • NCT07155174 · AbbVie · Phase 2 · live · background · “Lurbinectedin” · registered Aug 2025
  • NCT06203210 · Daiichi Sankyo · Phase 3 · live · comparator · “Lurbinectedin” · registered Jan 2024
PharmaMar74% of its industry studiesUS: JAZZ (FDA 2020)EU: Pharma Mar S.A. (EMA 2026)67 studies
CisplatinRecent, repeated
Evidence
  • NCT07802821 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Cisplatin” · registered Aug 2026
  • NCT07559929 · Hangzhou DAC Biotechnology Co., Ltd. · Phase 2 · live · background · “Cisplatin” · registered Apr 2026
  • NCT06897579 · Sino Biopharmaceutical Limited · Phase 2 · comparator · “Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection” · registered Mar 2025
  • NCT05566041 · EpicentRx, Inc. · Phase 3 · live · comparator · “Cisplatin/carboplatin plus etoposide” · registered Sep 2022
  • NCT05224141 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Jan 2022
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed55 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
  • NCT05620134 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2022
  • NCT04332653 · NeoImmuneTech · Phase 2 · background · “pembrolizumab (KEYTRUDA®)” · registered Mar 2020
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)44 studies
IrinotecanRecent, repeated
Evidence
  • NCT06954246 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan” · registered Apr 2025
  • NCT05731518 · Biocity Biopharmaceutics Co., Ltd. · Phase 2 · live · background · “Irinotecan” · registered Jan 2023
  • NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Irinotecan (drug)” · registered Dec 2022
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)44 studies
tislelizumabRecent, repeated
Evidence
  • NCT07802821 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Tislelizumab” · registered Aug 2026
  • NCT07502300 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Tislelizumab” · registered Mar 2026
  • NCT06897579 · Sino Biopharmaceutical Limited · Phase 2 · comparator · “Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection” · registered Mar 2025
  • NCT06030258 · InxMed (Shanghai) Co., Ltd. · Phase 2 · live · background · “Tislelizumab” · registered Sep 2023
BeOne Medicines72% of its industry studiesUS: BeOne Medicines (FDA 2024)EU: BeOne Medicines (EMA 2023)44 studies
amrubicinRecent, repeated
Evidence
  • NCT07365241 · AbbVie · Phase 3 · live · comparator · “Amrubicin” · registered Jan 2026
  • NCT06203210 · Daiichi Sankyo · Phase 3 · live · comparator · “Amrubicin” · registered Jan 2024
  • NCT05740566 · Amgen · Phase 3 · live · comparator · “Amrubicin” · registered Feb 2023
  • NCT01904253 · Otsuka Holdings Co., Ltd. · Phase 2 · comparator · “Amrubicin (Japan)” · registered Jul 2013
Bristol-Myers Squibb67% of its industry studies33 studies
durvalumabRecent, repeated
Evidence
  • NCT07908537 · Merck & Co., Inc · Phase 3 · live · background · “Durvalumab” · registered Oct 2026
  • NCT07174583 · IDEAYA Biosciences · Phase 2 · live · background · “durvalumab” · registered Sep 2025
  • NCT06780137 · Merck & Co., Inc · Phase 2 · live · background · “Durvalumab” · registered Jan 2025
  • NCT06211036 · Amgen · Phase 3 · live · background · “Durvalumab” · registered Jan 2024
AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018)34 studies
PaclitaxelRecent, repeated
Evidence
  • NCT06954246 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2025
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
  • NCT04210037 · Ascentage Pharma Group International · Phase 2 · background · “Paclitaxel” · registered Dec 2019
  • NCT02038647 · Takeda · Phase 2 · background · “Paclitaxel” · registered Dec 2013
  • NCT00527735 · Bristol-Myers Squibb · Phase 2 · background · “Paclitaxel” · registered Sep 2007
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed22 studies
enzalutamideRecent, repeated
Evidence
  • NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
  • NCT05551117 · MacroGenics · Phase 2 · comparator · “Enzalutamide” · registered Sep 2022
Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized22 studies
Abiraterone AcetateRecent, repeated
Evidence
  • NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
  • NCT05551117 · MacroGenics · Phase 2 · comparator · “Abiraterone” · registered Sep 2022
Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized22 studies

22 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
izalontamab brengitecan☆ Track2 live phase-3 studies: NCT07502300, NCT06500026Sichuan Biokin Pharmaceutical Co., Ltd.
Megestrol AcetatePhase 4 trial recorded☆ Track1 live phase-3 study: NCT06961201Changchun GeneScience Pharmaceutical Co., Ltd.
Anti-B7-H3 Antibody-drug Conjugate MHB088C☆ Track1 live phase-3 study: NCT06954246Qilu Pharmaceutical Co., Ltd.
trilaciclibApproved: US 2021☆ Track1 live phase-3 study: NCT07881705Simcere Pharmaceutical Group Limited
atigotatug☆ Track1 live phase-3 study: NCT06646276Bristol-Myers Squibb

The 5 in phase 3 with the nearest primary completion, of 100 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (19)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 main aimNCT05924841 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer — primary endpoint: Objective response rate (ORR) · 100 enrolled
  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 main aimNCT06437509 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer — primary endpoint: Objective Response Rate (ORR) · 66 enrolled
  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 main aimNCT06500026 A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) — primary endpoint: Overall survival (OS) · 722 enrolled

16 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Small Cell Lung Carcinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 72 open · Tyrosine kinase inhibitors (TKIs) 27 open · Antibody-drug conjugates (ADCs) 5 open · Antimitotic agents 4 open · Antimetabolites 3 open

Coming up

131studies finish main data collection within a year15 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger. 3 (1%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 8 (3%) take healthy volunteers.

Recruiting studies that take each age, of 265
AgeWomenMen
101 (<1%)1 (<1%)
18258 (97%)258 (97%)
30262 (99%)262 (99%)
40262 (99%)262 (99%)
50264 (100%)264 (100%)
65265 (100%)265 (100%)
75258 (97%)258 (97%)
85190 (72%)190 (72%)

Across all 1,302 studies, recruiting or not: 19% stop at 75 or younger and 1% at 65; 3% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Small Cell Lung Carcinoma studies take

Of 204 phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 146 mo29–64 · 143 studies44 mo29–63 · 111 studies—
Phase 1/254 mo44–97 · 98 studies54 mo43–74 · 71 studies—
Phase 246 mo29–84 · 204 studies35 mo18–44 · 54 studies53 mo36–87 · 150 studies
Phase 341 mo31–48 · 68 studies34 mo30–44 · 55 studies—
Interventional, no phase52 mo25–73 · 47 studies—52 mo26–73 · 45 studies
Observational77 mo47–… · 62 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered14

Show 9 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,302. Browse all 1,302 → or search them.